NeOnc Technologies Holdings Inc
NTHI
Company Profile
Business description
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (“FDA”).
Contact
8335 Sunset Boulevard
Suite 240
Los AngelesCA90069
USAT: +1 310 663-7831
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,524.80 | 55.10 | -0.64% |
| CAC 40 | 7,834.56 | 52.13 | -0.66% |
| DAX 40 | 23,754.11 | 13.32 | -0.06% |
| Dow JONES (US) | 42,654.74 | 331.99 | 0.78% |
| FTSE 100 | 8,630.33 | 54.23 | -0.62% |
| HKSE | 23,332.72 | 12.33 | -0.05% |
| NASDAQ | 19,211.10 | 98.78 | 0.52% |
| Nikkei 225 | 37,498.63 | 255.09 | -0.68% |
| NZX 50 Index | 12,629.07 | 157.72 | -1.23% |
| S&P 500 | 5,958.38 | 41.45 | 0.70% |
| S&P/ASX 200 | 8,295.10 | 48.60 | -0.58% |
| SSE Composite Index | 3,367.58 | 0.12 | 0.00% |